ACTEIN

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C37H56O11
Molecular Weight	676.8339
Optical Activity	UNSPECIFIED
Defined Stereocenters	19 / 19
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

C[C@@H]1C[C@]2(O[C@H](O)[C@@]3(C)O[C@@H]23)O[C@H]4C[C@@]5(C)[C@@H]6CC[C@@H]7[C@]8(C[C@@]68C[C@@H](OC(C)=O)[C@]5(C)[C@@H]14)CC[C@H](O[C@@H]9OC[C@@H](O)[C@H](O)[C@H]9O)C7(C)C

InChI

InChIKey=NEWMWGLPJQHSSQ-PSDKAYTQSA-N

InChI=1S/C37H56O11/c1-17-12-37(29-34(7,47-29)30(42)48-37)46-20-13-32(5)22-9-8-21-31(3,4)23(45-28-27(41)26(40)19(39)15-43-28)10-11-35(21)16-36(22,35)14-24(44-18(2)38)33(32,6)25(17)20/h17,19-30,39-42H,8-16H2,1-7H3/t17-,19-,20+,21+,22+,23+,24-,25+,26+,27-,28+,29-,30+,32+,33-,34+,35-,36+,37-/m1/s1

HIDE SMILES / InChI

Molecular Formula	C37H56O11
Molecular Weight	676.8339
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	19 / 19
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/27483235 | https://www.ncbi.nlm.nih.gov/pubmed/18755149 | https://www.ncbi.nlm.nih.gov/pubmed/28128733

Actein is tetracyclic triterpenoid compound isolated from the rhizome of Cimicifuga foetida L. In North America, the cimicifuga species had a long medicinal history, mainly used to treat diarrhea, sore throat, and rheumatism. Actein inhibits the activity of the Na,K-ATPase, which affects calcium metabolism. The primary target of actein may relate to calcium metabolism since this agent altered the expression of several genes related to calcium. Although actein was shown to exhibit other pathological functions, such as prevention of oxidative damage to osteoblast and regulation of lipid disorder, the major role of actein is played on its anticancer activity, particularly in breast cancer.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Apoptosis 156 Target ID: WP254 Sources: https://www.ncbi.nlm.nih.gov/pubmed/28128733	Activator 1447
Release of calcium into the cytoplasm 1 Target ID: Release of calcium into the cytoplasm Sources: https://www.ncbi.nlm.nih.gov/pubmed/23939423	Activator 1447
Sodium/potassium-transporting ATPase 34 Target ID: CHEMBL2095186 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18755149	Inhibitor 8504	11.2 µM [IC50]

Conditions

Condition	Modality	Highest Phase	Product
Breast cancer 432 Sources: https://www.ncbi.nlm.nih.gov/pubmed/27731376	Primary	Preclinical	Unknown Approved Use Unknown
Glioma 25 Sources: https://www.ncbi.nlm.nih.gov/pubmed/28128733	Primary	Preclinical	Unknown Approved Use Unknown
Liver cancer 53 Sources: https://www.ncbi.nlm.nih.gov/pubmed/28110190	Primary	Preclinical	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
Actein alleviates 2,3,7,8-tetrachlorodibenzo-p-dioxin-mediated cellular dysfunction in osteoblastic MC3T3-E1 cells.	2017-12	28836330
New potential beneficial effects of actein, a triterpene glycoside isolated from Cimicifuga species, in breast cancer treatment.	2016-10-12	27731376
The in Vitro and in Vivo Antitumor Activities of Tetracyclic Triterpenoids Compounds Actein and 26-Deoxyactein Isolated from Rhizome of Cimicifuga foetida L.	2016-07-30	27483235
Actein induces calcium release in human breast cancer cells.	2013-12	23939423
Actein inhibits the Na+-K+-ATPase and enhances the growth inhibitory effect of digitoxin on human breast cancer cells.	2008-10-31	18755149
[Actein, a fluid extract from Actaea racemosa, in the medical therapy of peripheral arteriopathies].	1962-05-15	13916295

Patents

Sample Use Guides

In Vivo Use Guide

Mouse: 10-15 mg/kg for 28 days

Route of Administration: Oral

In Vitro Use Guide

MC3T3-E1 osteoblastic cells were pretreated with actein (0.01–1 uM) for 1 h and then exposed to 100 nM 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) for 48 h. Cell viability was again measured using the water-soluble tetrazolium (WST) assay. Actein-pretreated cells had increased viability compared to those treated with TCDD only, in a concentration-dependent manner. The TCDD-induced increased apoptosis was also restored to a level similar to that in the control group by pretreatment with 1 uM actein. Pretreatment with actein also prevented TCDD-induced autophagic activity in a concentration-dependent manner. Taking these findings together, pretreatment with actein protected MC3T3-E1 osteoblastic cells from TCDD-induced apoptosis

Substance Class	Chemical Created by `admin` on `Mon Mar 31 22:09:53 GMT 2025` Edited by `admin` on `Mon Mar 31 22:09:53 GMT 2025`
Record UNII	I14QO4LW9V
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

26S-ACTEIN

Preferred Name

English

ACTEIN

Common Name

English

Actein [WHO-DD]

Common Name

English

ACTEIN [USP-RS]

Common Name

English

26S-ACTEIN (CONSTITUENT OF BLACK COHOSH) [DSC]

Common Name

English

ACTEIN, (-)-

Common Name

English

SHENGMATING

Common Name

English

.BETA.-D-XYLOPYRANOSIDE, (3.BETA.,12.BETA.,16.BETA.,23R,24R,25S,26S)-12-(ACETYLOXY)-16,23:23,26:24,25-TRIEPOXY-26-HYDROXY-9,19-CYCLOLANOSTAN-3-YL

Systematic Name

English

Code System Code Type Description

CAS

18642-44-9